Status:
COMPLETED
Cognitive Effects of Immunomodulatory Drugs in MS
Lead Sponsor:
Sharon Lynch, MD
Collaborating Sponsors:
EMD Serono
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Brief Summary
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Co...
Detailed Description
In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.
Eligibility Criteria
Inclusion
- Diagnosis of RRMS for at least one year,
- Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
- Visual Acuity is 20/50 or better,
- patient has four color vision,
- Must have at least a high school education
Exclusion
- History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
- currently taking immunosuppressant medication,
- resides greater than 200 miles from the study site
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00229502
Start Date
September 1 2005
End Date
December 1 2011
Last Update
March 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160